In the past week, EWTX stock has gone up by 1.41%, with a monthly gain of 3.66% and a quarterly plunge of -0.92%. The volatility ratio for the week is 4.11%, and the volatility levels for the last 30 days are 5.80% for Edgewise Therapeutics Inc The simple moving average for the past 20 days is -4.57% for EWTX’s stock, with a 9.69% simple moving average for the past 200 days.
Is It Worth Investing in Edgewise Therapeutics Inc (NASDAQ: EWTX) Right Now?
The 36-month beta value for EWTX is at 0.19. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EWTX is 58.32M, and currently, shorts hold a 13.35% of that float. The average trading volume for EWTX on September 12, 2024 was 883.80K shares.
EWTX) stock’s latest price update
The stock price of Edgewise Therapeutics Inc (NASDAQ: EWTX) has surged by 5.14 when compared to previous closing price of 16.85, but the company has seen a 1.41% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-05 that Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an experienced management team and strong financials. Sevasemten offers a genotype-agnostic approach, competitive difference from dystrophin-targeting therapies, with potential high market valuation.
Analysts’ Opinion of EWTX
Many brokerage firms have already submitted their reports for EWTX stocks, with Piper Sandler repeating the rating for EWTX by listing it as a “Overweight.” The predicted price for EWTX in the upcoming period, according to Piper Sandler is $48 based on the research report published on March 07, 2024 of the current year 2024.
Goldman gave a rating of “Sell” to EWTX, setting the target price at $5 in the report published on August 25th of the previous year.
EWTX Trading at -6.61% from the 50-Day Moving Average
After a stumble in the market that brought EWTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.61% of loss for the given period.
Volatility was left at 5.80%, however, over the last 30 days, the volatility rate increased by 4.11%, as shares surge +6.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.09% lower at present.
During the last 5 trading sessions, EWTX rose by +4.06%, which changed the moving average for the period of 200-days by +180.99% in comparison to the 20-day moving average, which settled at $18.62. In addition, Edgewise Therapeutics Inc saw 61.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EWTX starting from MOORE JOHN R, who sale 1,956 shares at the price of $18.91 back on May 02 ’24. After this action, MOORE JOHN R now owns 3,252 shares of Edgewise Therapeutics Inc, valued at $36,988 using the latest closing price.
Carruthers R Michael, the Chief Financial Officer of Edgewise Therapeutics Inc, sale 2,157 shares at $18.91 during a trade that took place back on May 02 ’24, which means that Carruthers R Michael is holding 35,230 shares at $40,789 based on the most recent closing price.
Stock Fundamentals for EWTX
Current profitability levels for the company are sitting at:
- -60.47 for the present operating margin
- 0.09 for the gross margin
The net margin for Edgewise Therapeutics Inc stands at -51.46. The total capital return value is set at -0.26. Equity return is now at value -28.20, with -26.88 for asset returns.
Based on Edgewise Therapeutics Inc (EWTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -20.78. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -43.83.
Currently, EBITDA for the company is -112.62 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 718.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.24.
Conclusion
In conclusion, Edgewise Therapeutics Inc (EWTX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
